In addition, ILC2-deficient gp130;F/FR5-IL5;dtTomato-IRES-CreRosa26DTA/+ (gp130;F/FILC2Δ) compound mutant mice had a reduced tumor burdens compared to ILC2-proficient gp130;F/FILC2WT mice (Fig. 2d). This evidence concerns the gene IL5 and neoplasm.